Summit Therapeutics
SMMT
20 hedge funds and large institutions have $24.3M invested in Summit Therapeutics in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
82% more funds holding
Funds holding: 11 → 20 (+9)
22% more capital invested
Capital invested by funds: $19.9M → $24.3M (+$4.4M)
0.06% less ownership
Funds ownership: 2.5% → 2.44% (-0.06%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$3.45M |
| 2 |
Renaissance Technologies
New York
|
+$662K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$437K |
| 4 |
BP
BBR Partners
New York
|
+$172K |
| 5 |
CIP
Cornerstone Investment Partners
Atlanta,
Georgia
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPU
Lansdowne Partners (UK)
London,
United Kingdom
|
-$5.38M |
| 2 |
Morgan Stanley
New York
|
-$262K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$141K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$140K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$17K |
SMMT Hedge Fund Activity: Q2 2020 in Review
20 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2020, worth a combined $24.3M — up 22% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SMMT positions and 2 closed out — a net gain of 9 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Polar Capital, adding an estimated $3.45M. The largest seller was Lansdowne Partners (UK), cutting an estimated $5.38M.
- 20 institutional investors held Summit Therapeutics (SMMT) as of Q2 2020, up from 11 in Q1 2020.
- Funds reported $24.3M of Summit Therapeutics stock for Q2 2020, up 22% quarter-over-quarter.
- 11 funds opened new Summit Therapeutics positions in Q2 2020 and 2 closed out, a net change of +9 holders.
- The largest Summit Therapeutics buyer in Q2 2020 was Polar Capital, an estimated $3.45M added.
- The largest Summit Therapeutics seller in Q2 2020 was Lansdowne Partners (UK), an estimated $5.38M sold.
Based on aggregated 13F filings for Q2 2020.